A new fertility drug, OXO-001, has shown significant potential to improve the rate of embryo implantation during IVF, leading to a 7% increase in live births.
The drug works by directly acting on the lining of the womb, making it more receptive to the embryo.
The trial, conducted across 28 centers in Europe, involved 96 women who underwent a single embryo transfer.
OXO-001 has the potential to be the first therapeutic treatment to increase embryo implantation success with a non-hormonal, targeted approach.
